1. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11, 785–797 (2010).
2. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18, 5–18 (2018).
3. Roumenina LT, Daugan MV, Petitprez F, Sautes-Fridman C, Fridman WH. Context-dependent roles of complement in cancer. Nat Rev Cancer 19, 698–715 (2019).
4. Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest 127, 780–789 (2017).
5. Ajona D, et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64, 6310–6318 (2004).
6. Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178, 5991–5998 (2007).
7. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 113, 173–182 (1998).
8. Wilczek E, et al. The possible role of factor H in colon cancer resistance to complement attack. Int J Cancer 122, 2030–2037 (2008).
9. Smolag KI, et al. Complement inhibitor factor H expressed by breast cancer cells differentiates CD14(+) human monocytes into immunosuppressive macrophages. Oncoimmunology 9, 1731135 (2020).
10. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 164, 6075–6081 (2000).
11. Junnikkala S, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 87, 1119–1127 (2002).
12. Riihila PM, et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 134, 498–506 (2014).
13. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 275, 16666–16672 (2000).
14. Cui T, et al. Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39, 161–168 (2011).
15. Olivar R, et al. The Complement Inhibitor Factor H Generates an Anti-Inflammatory and Tolerogenic State in Monocyte-Derived Dendritic Cells. J Immunol 196, 4274–4290 (2016).
16. Mao X, et al. Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. J Extracell Vesicles 10, e12031 (2020).
17. Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF, Jr. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 16, 3226–3231 (2010).
18. Campa MJ, Gottlin EB, Bushey RT, Patz EF, Jr. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. Cancer Immunol Res 3, 1325–1332 (2015).
19. Bushey RT, et al. A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Rep 15, 1505–1513 (2016).
20. Masucci MT, Minopoli M, Carriero MV. Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. Front Oncol 9, 1146 (2019).
21. Shaul ME, et al. Tumor-associated neutrophils display a distinct N1 profile following TGFbeta modulation: A transcriptomics analysis of pro- vs. antitumor TANs. Oncoimmunology 5, e1232221 (2016).
22. Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity 54, 875–884 (2021).
23. Cassetta L, et al. Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother 68, 687–697 (2019).
24. Dunkle A, Dzhagalov I, Gordy C, He YW. Transfer of CD8 + T cell memory using Bcl-2 as a marker. J Immunol 190, 940–947 (2013).
25. Grayson JM, Murali-Krishna K, Altman JD, Ahmed R. Gene expression in antigen-specific CD8 + T cells during viral infection. J Immunol 166, 795–799 (2001).
26. Lang BJ, Guerrero-Gimenez ME, Prince TL, Ackerman A, Bonorino C, Calderwood SK. Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond. Int J Mol Sci 20, (2019).
27. Frias AB, Jr., et al. The Transcriptional Regulator Id2 Is Critical for Adipose-Resident Regulatory T Cell Differentiation, Survival, and Function. J Immunol 203, 658–664 (2019).
28. Alshetaiwi H, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol 5, (2020).
29. Avery VM, Gordon DL. Characterization of factor H binding to human polymorphonuclear leukocytes. J Immunol 151, 5545–5553 (1993).
30. DiScipio RG, Daffern PJ, Schraufstatter IU, Sriramarao P. Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J Immunol 160, 4057–4066 (1998).
31. Losse J, Zipfel PF, Jozsi M. Factor H and factor H-related protein 1 bind to human neutrophils via complement receptor 3, mediate attachment to Candida albicans, and enhance neutrophil antimicrobial activity. J Immunol 184, 912–921 (2010).
32. Schneider AE, Sandor N, Karpati E, Jozsi M. Complement factor H modulates the activation of human neutrophil granulocytes and the generation of neutrophil extracellular traps. Mol Immunol 72, 37–48 (2016).
33. Chen SF, Wang FM, Li ZY, Yu F, Chen M, Zhao MH. Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by Interacting With Neutrophils. Front Immunol 9, 559 (2018).
34. Kasahara Y, et al. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 89, 1748–1753 (1997).
35. Licht C, et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 45, 415–421 (2005).
36. Wehling C, et al. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clin Exp Immunol 187, 304–315 (2017).
37. Westra D, et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol 32, 297–309 (2017).
38. Platt JL, et al. C3d regulates immune checkpoint blockade and enhances antitumor immunity. JCI Insight 2, (2017).
39. Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr Opin Immunol 17, 237–243 (2005).
40. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity 37, 199–207 (2012).
41. Miyazaki M, et al. Id2 and Id3 maintain the regulatory T cell pool to suppress inflammatory disease. Nat Immunol 15, 767–776 (2014).
42. Lu L, et al. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Res Immunol 3, 118–127 (2022).
43. McCarthy DJ, Campbell KR, Lun AT, Wills QF. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179–1186 (2017).
44. Stuart T, et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888–1902 e1821 (2019).
45. Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res 40, 3785–3799 (2012).
46. Aran D, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 20, 163–172 (2019).
47. Heng TS, Painter MW, Immunological Genome Project C. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol 9, 1091–1094 (2008).
48. Schapiro D, et al. histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. Nat Methods 14, 873–876 (2017).